Regeneron Pharmaceuticals: all 411 studies
Page 5 of 5. Open to participants first (93), then studies with results posted, then the rest; newest registration first within each.
- A Study of the Safety and Efficacy of REGN475(SAR164877) in Patients With Osteoarthritis of the KneeCompletedNCT00944892Phase 1/2
- A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid MalignanciesCompletedNCT00871559Phase 1
- A Single-Dose Study of the Safety and Tolerability of REGN475(SAR164877) in Healthy SubjectsCompletedNCT00856310Phase 1
- Study of the Safety and Effectiveness of Rilonacept (IL-1 Trap) Administered Subcutaneously in Subjects With Non Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) and AnemiaWithdrawnNCT00609544Phase 2
- Safety and Tolerability of Intravitreal VEGF Trap Formulations in Subjects With Neovacular AMDCompletedNCT00383370Phase 1
- Phase 1 Study of VEGF Trap in Patients With Diabetic Macular EdemaCompletedNCT00320814Phase 1
- Safety and Tolerability Study of Intravitreal VEGF-Trap Administration in Patients With Neovascular AMDCompletedNCT00320775Phase 1
- Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's LymphomaCompletedNCT00083213Phase 1
- Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's LymphomaCompletedNCT00082823Phase 1
- VEGF Trap in Treating Patients With Solid Tumors or Non-Hodgkin's LymphomaCompletedNCT00045266Phase 1
- VEGF Trap in Treating Patients With Relapsed or Refractory Solid Tumors or Non-Hodgkin's LymphomaCompletedNCT00036946Phase 1